Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.46 |
| ▸ | OGA | O60502 | 12/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343325 | 0.96 | SMN1; SMN2 (0.47) | GCKOGASMN1; SMN2KCNH2POLB | |
| SCHEMBL1342754 | 0.94 | OGA (0.51) | GCKOGASMN1; SMN2POLB | |
| SCHEMBL1343375 | 0.88 | SMN1; SMN2 (0.56) | OGASMN1; SMN2POLB | |
| SCHEMBL2651294 | 0.87 | GCK (0.38) | GCKOGASMN1; SMN2TDP1POLB | |
| SCHEMBL1343032 | 0.86 | SMN1; SMN2 (0.50) | GCKOGASMN1; SMN2KCNH2POLB | |
| SCHEMBL1343227 | 0.84 | SMN1; SMN2 (0.48) | OGASMN1; SMN2POLB | |
| SCHEMBL1343127 | 0.84 | SMN1; SMN2 (0.50) | OGASMN1; SMN2POLB | |
| SCHEMBL1341711 | 0.83 | SMN1; SMN2 (0.49) | OGASMN1; SMN2POLB | |
| SCHEMBL2650754 | 0.83 | SMN1; SMN2 (0.52) | OGASMN1; SMN2POLB | |
| SCHEMBL1342740 | 0.81 | POLB (0.43) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |